Ultime notizie per Grupo Supervielle (NYSE:SUPV) Azioni

Grupo Supervielle

Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.

Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) has outperformed the market over the past 5 years by 10.81% on an annualized basis producing an average annual return of 25.34%. Currently, Kinsale Cap Gr has a market capitalization of $11.38 billion. 
Buying $100 In KNSL: If an investor had bought $100 of KNSL stock 5 years ago, it would be worth $306.62 today based on a price of $488.00 for KNSL at the time of writing.
<h3>Kinsale Cap Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752006613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

KNSL

Here's How Much $100 Invested In Kinsale Cap Gr 5 Years Ago Would Be Worth Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed up 64.00% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 20.23% at $0.27</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 19.05% at $0.12</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 18.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 16.69% at $0.59</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 16.45% at $0.97</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 12.22% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed up 12.08% at $1.38</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 10.24% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 9.09% at $0.30</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 8.82% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 8.11% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 7.36% at $0.54</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed up 5.60% at $1.32</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 5.39% at $0.18</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 4.10% at $5.72</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 4.02% at $2.11</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 3.96% at $0.30</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 3.32% at $0.09</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 26.98% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 23.53% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 23.30% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 17.69% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 12.37% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/ZLDAF">Zelira Therapeutics</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZLDAF#OTC">ZLDAF</a>) shares closed down 3.22% at $0.27</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BLGVF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNBX

CNTMF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CXXIF

ELLXF

FFNTF

GBHPF

GTBIF

ITHUF

KAYS

LMLLF

MRMD

NWVCF

RMHB

SNDL

SOLCF

TGIFF

TLRY

UGRO

ZLDAF

Marijuana Stock Movers For July 8, 2025

Guidance

Penguin Solutions, Inc. - Ordinary Shares

PENG

Penguin Solutions Raises FY2025 Adj EPS Guidance from $1.50-$1.70 to $1.75-$1.85 vs $1.62 Est; Narrows FY2025 Sales Guidance from $1.33B-$1.41B to $1.35B-$1.39B vs $1.37B Est

WIIM

COGT

Cogent Biosciences shares are trading lower after the company announced a proposed $150 million public offering of common stock.

Voya Financial, Inc. (the "Company", "we" and "our") is furnishing this Current Report on Form 8-K to disclose alternative investment income above (below) long-term expectations prior to the availability of the Company's quarterly earnings release and quarterly financial supplement for the quarter ended June&nbsp;30, 2025, scheduled for release on August&nbsp;5, 2025.
For the second quarter 2025, the Company's alternative investment income is estimated to be approximately $45 million - $55 million (pre-tax), which is approximately $5 million below - $5 million above our long-term expectations, before variable and incentive compensation. Included in these figures is alternative investment income in our general account and investment capital returns in our Investment Management segment.
The long-term expectation for alternative investments is a 9% annual return.

VOYA

Voya Financial Estimates Q2 2025 Alternative Investment Income At $45M–$55M Pre-Tax, Or ~$5M Below To $5M Above Long-Term Expectations

Cogent Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cogt#NASDAQ">COGT</a>), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $150 million of its shares of common stock. In addition, Cogent intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its shares of common stock on the same terms and conditions. All of the securities in the offering are being offered by Cogent. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Cogent intends to use the net proceeds from the offering for continued development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, activities to support the planned commercial launch of bezuclastinib, as well as for working capital and general corporate purposes.
J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is also acting as lead manager for the offering.

Offerings

Small Cap

Cogent Biosciences Announces Proposed $150M Public Offering Of Common Stock

On July 18, 2022, Grove Collaborative Holdings, Inc. (the "Company") entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, Ltd. ("Yorkville") whereby the Company has the right, but not the obligation, to sell to Yorkville up to $100.0 million of its shares of Class A common stock, par value $0.0001 per share (the "Common Stock"), at the Company's request during the 36 months following the execution of the SEPA, subject to certain conditions.
 &nbsp;
On July&nbsp;8, 2025, the Company and Yorkville entered into the Amendment to Standby Equity Purchase Agreement (the "SEPA Amendment"), in which the Company and Yorkville agreed to: (1) change the definition of "Market Price" from the average VWAP (as defined below) of the Common Stock during the three consecutive trading days commencing on the notice date to the lowest of the daily VWAP of the Common Stock during such three consecutive trading day period, and (2) extend the commitment period under the SEPA to August 1, 2027. "VWAP" means, for any trading day, the daily volume weighted average price of the Company's Class A common stock for such date on the New York Stock Exchange as reported by Bloomberg L.P. during regular trading hours.
 &nbsp;
The foregoing description of the SEPA Amendment is qualified in its entirety by reference to the full text of the SEPA Amendment, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and which is incorporated herein by reference.
 &nbsp;

Contracts

GROV

Grove Collaborative Holdings Amends SEPA, Extends To August 2027; SEPA With Yorkville For $100M Stock Sale

Shares of solid-state battery developer QuantumScape Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) jumped sharply Tuesday in a session marked by heavy trading volume but a lack of fresh company-specific news. The stock&#8217;s upward momentum appears to be a delayed reaction to a key production announcement from late June.
What To Know: Investors appear to be <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46120118/why-quantumscape-qs-stock-is-exploding-higher-this-week">continuing to rally</a> behind the company&#8217;s late-June disclosure of the successful integration of its advanced Cobra separator process into its baseline cell production. 
This manufacturing milestone is a critical step for the solid-state battery developer as it progresses toward large-scale commercialization of its innovative battery technology.
The Cobra process is a leap forward, designed to enable faster and more energy-efficient production of the company's proprietary ceramic separators, a core component of its lithium-metal batteries. 
According to QuantumScape, the new process boasts a <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46098476/quantumscape-stock-is-soaring-wednesday-heres-why">25-fold improvement</a> in the speed of heat treatment compared to the prior-generation "Raptor" process.
Dr. Siva Sivaram, CEO of QuantumScape, highlighted the development&#8217;s importance, stating, &#8220;By significantly improving throughput and shrinking the equipment footprint, Cobra gives us a powerful path forward for commercializing our next-generation battery technology.&#8221; 
This leap in manufacturing efficiency is likely being viewed by investors as a crucial step toward establishing a scalable gigafactory production line.
Trading Volume Data: According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>,&nbsp;QuantumScape experienced exceptionally high trading volume on Tuesday, with 72.36 million shares changing hands. This is more than three and a half times its 100-day average volume of 20.386 million shares. 
Additionally, the stock has significant short interest, with 15.45% of its 442.245 million-share float currently sold short. 
QS Price Action: Quantumscape shares closed Tuesday up 16.69% to $8.18. The stock has a 52-week high of $9.52 and a 52-week low of $3.40.
This latest spike is part of a larger upward trend, with the stock climbing over 25% in the last five days and an impressive 88% over the past month.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46084743/quantumscape-stock-is-surging-after-the-bell-whats-fueling-the-move">QuantumScape Stock Is Surging After The Bell: What&#8217;s Fueling The Move?</a>
<h1 class="wp-block-heading">How To Buy QS Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, QuantumScape is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

Tech

QuantumScape (QS) Stock Jumps 15% On Massive Volume: What's Driving the Rally?

Kurv Investment Management launched the Kurv Gold Enhanced Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/KGLD#BATS">KGLD</a>), a new approach to gold investing that promises more than superficial diversification.
Rather than merely tracking the price of gold, KGLD seeks to produce monthly income by employing options strategies on gold exchange-traded products (ETPs), basically turning the precious metal from a passive safe haven into a tax-sophisticated yield vehicle.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/07/46304398/wisdomtrees-new-geoa-etf-bets-on-geopolitics-tech-shifts-and-global-power-plays">WisdomTree&#8217;s New GEOA ETF Bets On Geopolitics, Tech Shifts, And Global Power Plays</a>
Gold has been on a tear this year, rising about 25–27% in the last six months. Prices recently flirted with $3,500/oz, spurred by rising geopolitical tensions, inflation concerns, and a wave of central bank purchases. Institutional demand for <a href="https://www.benzinga.com/etfs">gold ETFs</a> is booming. 2025 experienced the highest inflows since 2020, with more than $38 billion pumped in during H1, according to Reuters, which cited WGC data.
Even with its stellar performance, conventional holdings of gold have detriments: no return in the form of income, as well as concealed expenses such as insurance, storage, and suboptimal treatment on capital gains taxation. Step forward Kurv&#8217;s KGLD, a new approach to gold investing which aims to provide monthly income, improve returns relative to spot gold, and be tax-effective, yet still provide gold exposure.
The plan with KGLD is to place options on gold ETPs to provide amplified income while attempting to do better than the price return of bullion, which other gold ETFs, such as GLD or IAU, can&#8217;t provide. It&#8217;s all part of Kurv&#8217;s mission to democratize institutional-quality strategies for individual investors and advisors.
Briefly, Kurv is bringing KGLD onto the scene at the perfect time when gold hunger is running hot, but traditional gold falls short. This ETF brings yield, solves tax and cost drag, and plays off the prevailing macro environment of uncertainty and gold&#8217;s all-time high momentum.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/07/46304047/energy-etfs-in-focus-after-exxon-flags-1-5-billion-profit-hit">Energy ETFs In Focus After Exxon Flags $1.5 Billion Profit Hit</a></li>
</ul>
Image: Shutterstock

New ETFs

Commodities

ETFs

Kurv ETF Trust Kurv Gold Enhanced Income ETF

KGLD

Kurv's KGLD ETF Turns Gold Gains Into A Monthly Paycheck As Prices Soar

<a href="https://www.bloomberg.com/news/articles/2025-07-08/starbucks-said-to-draw-interest-for-controlling-stake-in-china">https://www.bloomberg.com/news/articles/2025-07-08/starbucks-said-to-draw-interest-for-controlling-stake-in-china</a>

General

SBUX

'Starbucks Draws Interest for Controlling Stake in China'- Bloomberg

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has spoken out about the &#8220;Big Beautiful Bill&#8221; backed by President Donald Trump and Congress on several occasions. The bill will make it <a href="https://www.benzinga.com/news/politics/25/07/46283137/trump-vs-bezos-how-big-beautiful-bill-may-wreck-20k-ev-dream">more expensive for consumers</a> to buy electric vehicles and provide less credits for EV companies.
One analyst says the bill will hurt Tesla in more ways than one. &nbsp;
The Tesla Analyst: William Blair analyst Jed Dorsheimer downgraded Tesla stock from &#8220;Outperform&#8221; to &#8220;Market Perform&#8221; in a recent investor note. The analyst does not have a price target on the stock.
Read Also: <a href="https://www.benzinga.com/news/politics/25/07/46300946/musk-vs-trump-soap-opera-must-end-tesla-analyst-shares-3-key-steps">Musk Vs. Trump &#8216;Soap Opera Must End&#8217;: Tesla Analyst Shares 3 Key Steps</a>
The Analyst Takeaways: The recently passed "Big Beautiful Bill" could be "too much" for Tesla stock to overcome, Dorsheimer said in a new investor note.
The analyst said the removal of the $7,500 EV tax credit for consumers was expected, but the elimination of the corporate average fuel economy (CAFE) fines was less expected and requires a reset.
"While the $7,500 tax credit is likely to affect demand, the combination of a demand headwind and over $2 billion in profit from regulatory credits at risk may be too much for investors to bear," Dorsheimer said.
The loss of the EV $7,500 tax credit could negatively impact demand for Tesla vehicles among consumers. The removal of regulatory credit revenue could directly hit Tesla's profitability, the analyst adds.
"No More CAFÉ Fines, No More Credit Buyers."
The analyst said the bill eliminates market demand for Tesla's credits. The company earned $2.8 billion from selling these credits in 2024, making up 16% of its total gross profit.
Dorsheimer estimates that 75% of Tesla's regulatory credit revenue is related to the CAFE standards and now gets zeroed out in 2027.
The analyst stated that the removal of the $7,500 consumer tax credit could lead to an increase in unit volumes in the third quarter and put pressure on the fourth-quarter figures.
Along with the weakened demand and lower profits from regulatory credits, the analyst cites Musk's political push as a potential distraction for the electric vehicle company.
"We expect that investors are growing tired of the distraction at a point when the business needs Musk's attention the most and only see downside from his dip back into politics."
The analyst said Tesla stock now trades at an enterprise value of 76 times its lowered 2026 EBITDA estimates.
Risks for Tesla from the analyst include competition, geopolitics and "key-man risk" with Musk.
TSLA Price Action: Tesla stock was up 1.3% Tuesday to $297.81 versus a 52-week trading range of $182.00 to $488.54. Tesla stock is down 20.4% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46303314/heres-how-much-1000-invested-in-tesla-stock-today-will-be-worth-if-cathie-woods-price-prediction-comes-true-in-2029-2">Here&#8217;s How Much $1,000 Invested In Tesla Stock Today Will Be Worth If Cathie Wood&#8217;s Price Prediction Comes True In 2029</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Short Ideas

Downgrades

Analyst Ratings

TSLA

Trump's 'Big Beautiful Bill' Too Much For Tesla Stock: 'Direct Hit To Profitability'

Strategic alternatives, including a full sale of the business, must be pursued in order to unlock the full value of the platform.
Believes Grove could be conservatively valued at ~0.70x - 0.90x 2025E revenue in such a transaction, which equates to a ~90 - 140% premium to the Company's current share price of $1.19 or ~$2.25 - $2.90 per share on a fully diluted basis.
MIAMI , July 8, 2025 /PRNewswire/ -- HumanCo Investments ("HCI"), which is affiliated with investors that own more than 5% of Grove Collaborative Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) ("Grove" or the "Company") and are among the Company's largest shareholders, today sent a public letter to Grove's Board of Directors. The letter called on the Board to conduct a comprehensive review of strategic alternatives, including a sale to a larger strategic company or financial sponsor, or a transformative merger with a profitable company.

HumanCo Urges Grove Collaborative To Pursue Strategic Alternatives Including Full Sale; Estimates $2.25–$2.90/Share Valuation, A 90–140% Premium To Current Price

EVTL

Vertical Aerospace shares are trading lower after the company announced a $60 million offering.

SOBR

SOBR Safe shares are trading higher after the company announced it has been granted European patent number EP4171362.

<a href="https://www.sec.gov/Archives/edgar/data/1867102/000110465925066411/tm2520017-1_424b5.htm" title="https://www.sec.gov/Archives/edgar/data/1867102/000110465925066411/tm2520017-1_424b5.htm">https://www.sec.gov/Archives/edgar/data/1867102/000110465925066411/tm2520017-1_424b5.htm</a>

Vertical Aerospace Files For $60M Offering

KRUS

Kura Sushi USA shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance.

Republic Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) has outperformed the market over the past 15 years by 8.71% on an annualized basis producing an average annual return of 20.96%. Currently, Republic Services has a market capitalization of $74.78 billion. 
Buying $1000 In RSG: If an investor had bought $1000 of RSG stock 15 years ago, it would be worth $17,179.47 today based on a price of $239.31 for RSG at the time of writing.
<h3>Republic Services's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752005714_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Republic Services 15 Years Ago Would Be Worth Today

AEHR

Aehr Test Systems shares are trading lower after the company reported worse-than-expected Q4 sales results.

ELPW

Elong Power Holding Entered Into Strategic Cooperation Agreement With Consumer Protection Agency of the Republic of Indonesia To Address Electricity Access Issues

Tyra Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that a late-breaking abstract has been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2025), taking place July 12-15, 2025 in San Francisco, CA.
Details of the poster presentation are below:
<ul>
<li>Title: "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia"</li>
<li>Abstract: SUN-730</li>
<li>Presenting Author: Jacqueline H. Starrett, Ph.D., Tyra Biosciences</li>
<li>Date/Time: July 13, 2025, 12:00 PM - 1:30 PM, ENDOExpo: Poster Area</li>
<li>Session: Session P70 - BONE AND MINERAL METABOLISM: Rare Bone and Genetic Disorders</li>
</ul>

TYRA

Tyra Biosciences Says Late-Breaking Abstract On TYRA-300 Preclinical Results Accepted For Presentation At ENDO 2025

Press Releases

Grupo Supervielle Reports 2Q24 and 1H24 Results

Grupo Supervielle S.A. Announces the Appointment of Gustavo Manriquez as CEO of Banco Supervielle

Grupo Supervielle Reports 3Q24 and 9M24 Results

Grupo Supervielle Reports 4Q24 and FY24 Results

Grupo Supervielle Announces Filing of the 2024 Annual Report on Form 20-F

Grupo Supervielle Reports 1Q25 Results

SUPV

Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares)

Grupo Aval Acciones

Credicorp

Banco BBVA Argentina

Banco De Chile

Banco Macro S.A. ADR (representing Ten Class B Common Shares)

Banco Macro

Banco Santander Chile

Grupo Cibest S.A. American Depositary Shares each representing four Preferred Shares

Grupo Cibest

Comerica

Grupo Financiero Galicia S.A. - American Depositary Shares, Class B Shares underlying

Grupo Financiero Galicia

Intercorp Financial Services Inc. Common Shares

Intercorp Financial Servs

Inter & Co

Grupo Supervielle S.A. American Depositary Shares each Representing five Class B shares

Woori Financial Group Inc. American Depositary Shares (each representing three (3) shares of Common Stock)

Comments

Grupo Supervielle

Notizie

Ultime notizie per Grupo Supervielle (NYSE:SUPV) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO